What an MLR Committee Actually Reviews Before Approving Your Medical Material

Every medical presentation, Q&A, or commercial material a pharmaceutical team produces goes — or should go — through a Medical, Legal, and Regulatory (MLR) review before reaching a healthcare professional or a patient. Understanding what that committee actually evaluates, before submitting the material, saves entire cycles of back-and-forth.

The medical review in the MLR process centers on one concrete point: verifying that every data point and every claim about the product is grounded in adequate scientific evidence. An observational study published in Cureus, which analyzed promotional literature distributed in outpatient offices and scientific journals, found non-compliance findings against the World Health Organization's (WHO) ethical criteria for drug promotion and India's pharmaceutical industry code of ethics — underscoring why upfront verification matters before material reaches circulation ^[1].

In practice, a medical reviewer typically focuses on three questions: Is the claim supported by the cited source, without extrapolation? Is safety information and are contraindications presented with the same weight as benefits? Does the material stay within the approved indication, without suggesting unauthorized uses? This last question is particularly sensitive in Colombia, where current regulation requires that promotional and non-promotional content aimed at healthcare professionals align with the product's sanitary registration conditions ^[2].

The most efficient way to reduce an MLR committee's cycle time isn't rushing the review — it's preparing better for it: submitting material with every claim already traced to its source, with risk information balanced from the first draft, and with language verified against the approved indication. That upfront work — the same work that underpins a well-built dossier — is what separates a one-round approval from material that bounces three or four times before it ever reaches the field.